About Erasca
Erasca is a publicly listed company based in San Diego (United States) founded in 2018. It operates as a small molecule therapeutics for cancer treatment are developed. Erasca has raised $300 million across 5 funding rounds from investors including Orbimed, Arch Venture Partners and TMCP. The company has 103 employees. Erasca offers products and services including MAPKlamp and RAS Targeting Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ERASCA, INC. Its competitors include Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Erasca was founded in 2018 in San Diego, United States, within the biotechnology sector. Small molecule-based therapeutics are developed by the company to address oncology needs. Product candidates including naporafenib, ERAS-007, and ERAS-80 are advanced for melanoma and tissue-agnostic solid tumors. Operations focus on drug discovery and clinical development in the United States.
- Headquarters San Diego, United States
- Employees 103
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website erasca.com
- Social LinkedIn X
- Legal Name Erasca, Inc.
- Net Profit-$124.55 M (USD)22.95as on Dec 31, 2025
- EBITDA-$128.3 M (USD)13.68as on Dec 31, 2025
- Total Equity Funding$300M (USD)
in 5 rounds
- Latest Funding Round$45M (USD), Post-IPO
Mar 2024
- InvestorsOrbimed
& 11 more
- Employee Count103
Products & Services of Erasca
Erasca offers a comprehensive portfolio of products and services, including MAPKlamp and RAS Targeting Therapies.
Targets MAPK pathway nodes for cancer treatment
Directly inhibits RAS mutations in cancer signaling
Funding Insights of Erasca
Erasca has successfully raised a total of $300M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $45 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $300M
- Total Rounds 5
- Last Round Post-IPO — $45M
- First Round $42M
(Dec 2018)
- Investors Count 12
All 5 funding rounds of Erasca with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $45M | Post-IPO | – | – | – |
| Aug 2020 | $36M | Series B | – | Orbimed, PFM Health Sciences | – |
| Apr 2020 | $200M | Series B | – | Arch Venture Partners, Cormorant Asset Management | |
| Mar 2019 | $22M | Series A | – | Reneo Capital, a16z | – |
| Dec 2018 | $42M | Series A | – | City Hill, Cormorant Asset Management | – |
12 investors in total: 12 institutional.
Investors in Erasca
Erasca has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Arch Venture Partners and TMCP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Private equity investments in China are managed by TMCP. | – | terramagnumcap.com | Chaoyang, China | |
Venture capital firm and foundation focused on biotech, cleantech, and media & entertainment, education, and more | – | cityhill.com | San Diego, United States | |
Private equity investments are managed by this USA-based firm. | – | coltventures.com | Dallas, United States | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | – | edbi.com | Singapore, Singapore | |
Healthcare startups are funded by this corporate-backed venture capital entity. | – | lifesciventure.com | New York, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Healthcare startups are funded by this venture capital firm. | – | cormorantassetmanagement.tcc.mode | Ponte Vedra, United States | |
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | – | a16z.com | - | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for Erasca
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Erasca
59 people are tracked at Erasca (31 in leadership, 13 in board & advisors, 15 in team); the tracked headcount is 103.
| Name | Role | Group |
|---|---|---|
Michael Varney | Chairman of R&D, SAB & Director | Leadership |
Dawei Xuan | VP of Clinical Pharmacology | Leadership |
Susan Zhao | Vp, Head Of SPA And Cdm, Biometrics | Leadership |
Les Brail | VP of Clinical Development | Leadership |
Jonathan E. Lim | Chairman, CEO & Co-Founder | Leadership |
David Chacko | Chief Business Officer | Leadership |
Rachel Cervantes | VP of Business Development | Leadership |
Minli Xie | VP of Pharmaceutical Development & Operations | Leadership |
Justin Parker | Director, Clinical Data Management | Leadership |
Shannon Morris | Chief Medical Officer | Leadership |
Timothy Grammer | Vice President Project Portfolio And Alliance Management | Leadership |
Rebecca Sutton | Sr. Director, Clinical Operations | Leadership |
Alison Tjosvold Milhous | Vice President, Accounting | Leadership |
Inma Rodriguez | Associate Director Of Accounting | Leadership |
Asq Cssbb Anna Butler | Sr. Director, Portfolio & Program Management | Leadership |
Lisa Tesvich | Chief People Officer | Leadership |
Guevara Rowand | Exec Director Talent Acquisition | Leadership |
Lorraine Lockwood | Executive Director, Human Resources | Leadership |
Lilia Koriazova | Sr. Director, Biologics Pharmaceutical Sciences | Leadership |
Jessica Silver | Director Quality Systems | Leadership |
39 more people are available in the full profile.
Complete people profiles for Erasca
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Erasca
Erasca is a publicly listed company on the NASDAQ with ticker symbol ERAS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2021
- Listed onNASDAQ: ERAS
- Listed entityErasca, Inc.
- Exchange sectorHealth technology
- ISINUS29479A1088
- Share price$14.78 (-4.4% on the day) · 2026-10-13
- Market capitalisation$5.17B
- EPS (diluted, trailing year)$-0.95
- Volume (last session)5,313,582
Financials of Erasca
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$124.5M | -$128.3M |
| 2024 | – | -$161.7M | -$148.6M |
| 2023 | – | -$125.0M | -$137.8M |
| 2022 | – | -$242.8M | -$244.8M |
| 2021 | – | -$122.8M | -$124.0M |
Detailed financial statements for Erasca
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Erasca
4 dated milestones of Erasca across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Erasca is founded.
- Funding First funding round of $42.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $45.0M.
Competitors of Erasca
Erasca has 8 listed competitors in our database, 8 of them funded. They include Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. |
Detailed competitors of Erasca
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Erasca
The website of Erasca (erasca.com) receives about 8.9K visits a month and ranks #5,064,389 among all websites worldwide, #5,841 in Biotechnology and Pharmaceuticals.
- Monthly visits8.9K
▲ 164.6% vs previous month
- Unique visitors1.5K
per month
- Global rank#5,064,389
among all websites
- Category rank#5,841
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.7
- Average visit25 sec
- DevicesDesktop 39% · Mobile 61%
Top companies in Oncology
10 companies that operate in the same segment as Erasca (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Erasca
Complete news archive for Erasca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Erasca
Erasca was founded in 2018.
Erasca is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Erasca is a funded company, having raised a total of $300M across 5 funding rounds to date. The company's 1st funding round was a Series A of $42M, raised on Dec 2018.
Erasca has 103 employees.
Erasca was founded in 2018 in San Diego, United States, within the biotechnology sector. Small molecule-based therapeutics are developed by the company to address oncology needs. Product candidates including naporafenib, ERAS-007, and ERAS-80 are advanced for melanoma and tissue-agnostic solid tumors. Operations focus on drug discovery and clinical development in the United States.
Erasca's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Erasca offers MAPKlamp and RAS Targeting Therapies.
Yes, Erasca is publicly traded on NASDAQ under the ticker symbol ERAS.
Erasca has 12 investors. Key investors include Orbimed, Arch Venture Partners, TMCP, City Hill, and Colt Ventures.
Erasca operates through Erasca, Inc..